NATICK, Mass.–(COMMERCIAL WIRE)–Naveris, Inc. broadcasts the submission of an abstract related to its flagship diagnostic check out for HPV DNA-TTMV (NavDx®) on the 2022 American Society of Scientific Oncology (ASCO) Annual Meeting occurring June 3-7, 2022 in Chicago almost.
Outcomes of TTMV-HPV DNA testing throughout the Part II NRG-HN002 medical trial for victims with p16-positive oropharyngeal most cancers dealt with with intensity-modulated radiation treatment (IMRT), with or with out cisplatin-containing chemotherapy, shall be shared on the presentation.
The small print of the presentation are as follows:
Title: Affiliation of plasma tumor tissue-modified viral HPV DNA (TTMV) with tumor burden, remedy kind, and finish consequence: a translational analysis of NRG-HN002.
Presenter: Sue S. Yom, MD, Ph.D., Professor and Vice Chair, Strategic Counsel, Division of Radiation Oncology; Professor, Otolaryngology-Head and Neck Surgical process, Univ. of California San Francisco (UCSF)
Presentation session date/time: The oral presentation will occur on Friday, June 3, 2022 from 3:45 to 6:45 pm EDT, in the midst of the session titled “Head and Neck Most cancers.”
Location: In particular person and keep streaming | S406
After the submission, the submitted info shall be accessible on the Naveris website at https://www.naveris.com.
About Naveris, Inc.
Naveris’ mission is to reinforce outcomes for 1000’s and 1000’s of people vulnerable to creating viral cancers. The company applies its progressive and proprietary experience to develop molecular diagnostics that enable early detection of viral cancers. Naveris’ first commercial-stage diagnostic, NavDx®, is a blood check out that helps the medical administration of victims with cancers introduced on by HPV. Since its launch in 2020, NavDx has been built-in into the every day medical comply with of larger than 675 physicians at 250 medical web sites, along with most principal US Oncology Services of Excellence. For further information, go to naveris. com.